Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development. Pandya DN, Bhatt N, Yuan H, Day CS, Ehrmann BM, Wright M, Bierbach U, Wadas TJ.. Chem Sci. 2017;8(3):2309-2314.
Enhancing tissue permeability with MRI guided preclinical focused ultrasound system in rabbit muscle: from normal tissue to VX2 tumor. Sun Y, Xiong X, Pandya D, Jung Y, Mintz A, Hayasaka S, Wadas TJ, Li KCP.. J Control Release. 2017;256():1-8.
Evaluation of a 3-hydroxypyridin-2-one (2,3-HOPO) based macrocyclic chelator for (89)Zr(4+) and its use for immunoPET imaging of HER2 positive model of ovarian carcinoma in mice. N Tinianow J, Pandya DN, Pailloux SL, Ogasawara A, Vanderbilt AN, Gill HS, Williams SP, Wadas TJ, Magda D, Marik J.. Theranostics. 2016;6(4):511-521.
Preliminary therapy evaluation of (225)Ac-DOTA-c(RGDyK) demonstrates that cerenkov radiation derived from (225)Ac daughter decay can be detected by optical imaging for in vivo tumor visualization. Pandya DN, Hantgan R, Budzevich MM, Kock ND, Morse DL, Batista I, Mintz A, Li KC, Wadas TJ.. Theranostics. 2016;6(5):698-709.
Di-macrocyclic terephthalamide ligands as chelators for the PET radionuclide zirconium-89. Pandya DN, Pailloux S, Tatum D, Magda D, Wadas TJ.. Chem Commun (Camb). 2015;51(12):2301-2303.
Permeabilizing the blood-brain-barrier with alpha-particle therapy [abstract]. Sattiraju A, Xiong XB, Pandya D, Sun Y, Jung Y, Wadas T, Li K, Mintz A.. J Nucl Med. 2015;56(3 Suppl 3):1230.
Molecular targeted alpha-particle therapy for oncologic applications. Wadas TJ, Pandya DN, Solingapuram Sai KK, Mintz A.. AJR Am J Roentgenol. 2014;203(2):253-260.
The development of copper radiopharmaceuticals for imaging and therapy. Shokeen M, Wadas TJ.. Med Chem. 2011;7(5):413-429.
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.